Century Therapeutics 주식 (NASDAQ: IPSC)

에 대한 최신 뉴스 Century Therapeutics (NASDAQ:IPSC) 주식

CENTURY THERAPEUTICS INC

Century Therapeutics

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Balancing Safe And Risky Investments

Equities

Markets

IPSC

센추리 테라퓨틱스(NASDAQ:IPSC) 주가는 수요일(27일)에 20.74% 상승한 주당 1.63달러로 마감하면서, 10월 1일 이후 거의 한 달 만에 가장 높은 가격 변동폭을 기록했다. 또한 주가는 2023년 12월 6일 이후 11개월여 만에 하루 만에 가장 큰 폭으로 상승한 것이다.

센추리 테라퓨틱스, 캐스딘 캐피털이 지분 5.4%로 높이면서 주가 20% 폭등

Century Therapeutics, Inc. - Common Stock

Century Therapeutics Inc

Stifel analyst David Grossman maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Hold and lowers the price target from $156 to $152.

News

Price Target

Analyst Ratings

PAYX

Stifel Maintains Hold on Paychex, Lowers Price Target to $152

Meta In Talks To Acquire Ai Voice Startup PlayAI

<ul>
<li>Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service</li>
<li>Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.
He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board.
At the AGM, where 80.4% of QIAGEN's issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million.
Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science &amp; Technology and Human Resources &amp; Compensation Committees.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner.
The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski.
Shareholders also approved the initiation of QIAGEN's first-ever annual cash dividend - a milestone that reflects QIAGEN's strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases.
The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025.
In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN's commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth.

Dividends

Buybacks

Management

QGEN

QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M

A new film about Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is in the works. Here's why Meta CEO<a href="https://www.benzinga.com/topic/mark-zuckerberg"> Mark Zuckerberg</a> might not be happy about seeing his company on the big screen.
What Happened: A sequel to the 2010 film "The Social Network," which Zuckerberg <a href="https://www.benzinga.com/news/21/10/23381351/5-things-you-might-not-know-about-facebooks-mark-zuckerberg-2">was highly critical of</a>, is in the works.
Tentatively titled "The Social Network Part II," the film comes from the Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) unit of Sony Pictures, according to a report from <a href="https://deadline.com/2025/06/the-social-network-sequel-aaron-sorkin-1236439539/">Deadline</a>. According to the report, the film will not be a straight sequel, but rather a follow-up to the first film.
Aaron Sorkin, who wrote the screenplay for the first film, is returning to write the screenplay and direct the film. David Fincher, who directed the first film, is not mentioned in the report on the sequel.
While the first film was based on the book "The Accidental Millionaires" by Ben Mezrich, the new movie will focus on the story "The Facebook Files" from the Wall Street Journal. That story exposed the inner workings of Facebook and the potential harm it has done.
Sorkin has been vocal about wanting to do a follow-up to the hit 2010 movie; now it appears he&#8217;s found his angle with "The Facebook Files."
The writer and director also said in an interview last year that he believes Facebook played a role in the Jan. 6 attack on the U.S. Capitol. The new film won't focus solely on Jan. 6 or the 2020 election. It will also examine the potential harmful impact of Facebook on teenagers and preteens.
Todd Black, Peter Rice, Stuart Besser and Sorkin will produce the film. A production date has not been announced, with Sorkin likely working on casting first.
It is unknown if Jesse Eisenberg, who played Zuckerberg in the 2010 film, will return for the follow-up movie.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: The 2010 film focused on the early days of Facebook&#8217;s creation. It examined several disputes, including those between Zuckerberg and key figures in the company&#8217;s early days, such as the Winklevoss twins and Eduardo Saverin.
Zuckerberg has criticized that film on several occasions, saying it had many inaccuracies.
"It's interesting what stuff they focused on getting right; like, every single shirt and fleece that I had in that movie is actually a shirt or fleece that I own. So there's all this stuff that they got wrong and a bunch of random details that they got right," Zuckerberg said.
Zuckerberg may be even more concerned about the second movie as it will center on a report that sheds a negative light on the social media company.
"The Social Network" grossed $97 million domestically and $225 million globally, according to BoxOfficeMojo.
The film won three Academy Awards for Best Adapted Screenplay, Best Film Editing and Best Original Score. The film was nominated for eight Academy Awards, including top categories like Best Picture, Best Director and Best Actor for Eisenberg.
Meta Platforms&#8217; stock is up 233% over the last five years. Shareholders will closely watch the timing of the movie release to see if the film could harm the company's brand and share price.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs</a></li>
</ul>
Photo: Shutterstock

Entertainment

Sony Group Corporation American Depositary Shares

SONY

Mark Zuckerberg Hated 'The Social Network' Film: Don't Tell Him A Sequel Is Coming

Stifel analyst Brian Chin maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $130 to $145.

Stifel Maintains Buy on Micron Technology, Raises Price Target to $145

<a href="https://www.youtube.com/watch?v=vIRh3tzaJ48" title="https://www.youtube.com/watch?v=vIRh3tzaJ48">https://www.youtube.com/watch?v=vIRh3tzaJ48</a>

Macro Economic Events

Politics

Global

Economics

General

White House Says No Indication That Any Enriched Uranium Was Removed From Any Sites In Iran

Stifel analyst Matthew Smith maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Buy and lowers the price target from $65 to $56.

Stifel Maintains Buy on General Mills, Lowers Price Target to $56

Stifel analyst Erik Rasmussen maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Buy and lowers the price target from $1050 to $1010.

EQIX

Stifel Maintains Buy on Equinix, Lowers Price Target to $1010

Stifel analyst Brad Reback maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Hold and raises the price target from $120 to $135.

DDOG

Stifel Maintains Hold on Datadog, Raises Price Target to $135

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang has admitted that he <a href="https://www.benzinga.com/general/education/25/05/45504571/does-jensen-huang-check-nvidia-stock-price-daily-2">doesn't check the price</a> of his company's stock every day. He might want to look at the stock now, as it has recently hit new all-time highs.
Here's a look back at how much Huang and other investors who bought or owned shares when the company went public have made.
Investing $1,000 in Nvidia at IPO: Nvidia became one of the&nbsp;<a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club" target="_blank" rel="noreferrer noopener">most valuable companies</a>&nbsp;in the world in May 2023, passing the $1 trillion market capitalization level.
Since that time, the company went on to pass the $2 trillion and $3 trillion market capitalization levels. At the time of writing, Nvidia is the&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/45763363/nvidia-overtakes-microsoft-as-the-worlds-most-valuable-company-with-3-4-trillion-market-cap-as-morgan-stanley-reaffirms-top-pick-status" target="_blank" rel="noreferrer noopener">most valuable company</a>&nbsp;in the world valued at $3.79 trillion, slightly ahead of Microsoft Corporation ($3.68 trillion).
Back in 1999, Nvidia held its initial price offering on Jan. 22, with shares priced at $12 each.
A $1,000 investment in the company would have allowed for the purchase of 83.33 shares at the time.
Since its IPO, Nvidia has undergone several stock splits, which have increased the number of shares held by shareholders. The stock had 2:1 splits in 2000, 2001, and 2006, a 3:2 split in 2007, a 4:1 split in July 2021, and the most recent 10:1 split in June 2024.
Today, the original 83.33 shares would total 39,998.4 shares after the stock splits.
The original $1,000 investment in Nvidia stock would be worth $6,214,951.39 based on a share price of $155.38. This represents a huge return for Nvidia IPO buyers with some potential millionaires created over the years.
For comparison, the same $1,000 invested in the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, would have underperformed Nvidia.
A $1,000 investment in SPY stock could have bought 12.82 shares at the time, based on an adjusted price of $78.03 on Jan. 22, 1999.
The $1,000 invested in the SPDR S&amp;P 500 ETF Trust would be worth $7,831.99 today.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
What Happened:&nbsp;Nvidia has been at the forefront of the AI revolution and growth as a leader in the sector, which helped boost the stock price over the last several years.
Since its was&nbsp;<a href="https://www.nvidia.com/en-us/about-nvidia/corporate-timeline/" target="_blank" rel="noreferrer noopener">founded&nbsp;</a>in 1993, Nvidia has sought to be at the forefront of technological advancements to help new industrial advancements.
In 1999, the company invented the Graphics Processing Unit, commonly known as GPU today. The GPU redefined the computer industry.
In 2012, Nvidia ushered in the modern era of AI with the AlexNet neural network, potentially showing the company ahead of others when it came to belief in the capabilities of artificial intelligence.
In March 2024. the company&nbsp;<a href="https://www.benzinga.com/news/24/03/37809836/nvidia-reveals-blackwell-gpu-highlights-partnerships-with-top-companies-at-gtc-the-whole-industry-is" target="_blank" rel="noreferrer noopener">unveiled the&nbsp;Blackwell GPU</a>,&nbsp;which could help the company further disrupt the growth of artificial intelligence.
What&#8217;s Next:&nbsp;Nvidia continues to&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter" target="_blank" rel="noreferrer noopener">draw praise from analysts</a>&nbsp;as one of the best plays on the growth of artificial intelligence.
The big question for investors today is if Nvidia will keep outperforming the overall market and be one of the top-performing stocks going forward.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" target="_blank" rel="noreferrer noopener">beat analyst estimates</a>&nbsp;in the first quarter for both revenue and earnings per share. Nvidia CEO&nbsp;Jensen Huang&nbsp;highlighted the continued growth of AI and the company&#8217;s new products seeing huge demand, which came despite restrictions on exports to China.
Huang added that demand for Nvidia&#8217;s AI infrastructure is &#8220;incredibly strong.&#8221;
"Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and NVIDIA stands at the center of this profound transformation," Huang said.
The future looks bright for Nvidia and time will tell if investors today can turn their thousands into millions of dollars in the future.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46117402/jensen-huang-closes-in-on-top-10-richest-list-with-nvidia-stock-at-new-highs-heres-how-much-he-needs">Jensen Huang Closes In On Top 10 Richest List With Nvidia Stock At New Highs: Here&#8217;s How Much He Needs</a></li>
</ul>
This article was previously published by Benzinga and has been updated.

Education

NVDA

If You Invested $1,000 In Nvidia Stock At IPO, Here's How Much You'd Have Now

Stifel analyst J. Bruce Chan upgrades Forward Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) from Hold to Buy and raises the price target from $21 to $29.

Upgrades

FWRD

Stifel Upgrades Forward Air to Buy, Raises Price Target to $29

Republic, a New York-based investment platform, has started offering <a href="https://www.benzinga.com/news/space/25/06/46012079/elon-musks-spacex-suffers-major-setback-as-starship-rocket-explodes-in-static-fire-test">tokenized exposure to SpaceX shares</a>, aiming to give retail investors access to private company stakes that were traditionally limited to large, accredited investors.
What Happened: The company's digital tokens, which do not confer direct ownership but provide exposure to share performance, will soon be available for purchase, with plans to expand the offering to other private giants like OpenAI, Anthropic, Stripe, X, Waymo, and Epic Games, <a href="https://www.wsj.com/finance/investing/republic-investing-tokens-companies-ipo-ccff7f91?mod=hp_lead_pos5">according</a> to The Wall Street Journal.
Republic co-CEO Andrew Durgee <a href="https://www.cnbc.com/2025/06/25/blockchain-investing-startup-republic-to-allow-users-to-buy-tokenized-spacex-shares.html">told</a> CNBC the initiative is designed to open doors for retail investors who have long been excluded from pre-IPO opportunities.
&#8220;The fact that retail investors couldn't own pre-IPO SpaceX has always been crazy to us," Durgee said, emphasizing the company's focus on assets with broad public interest.
Tokenization in crypto involves creating blockchain-based representations of assets like stocks or commodities. Investors in these tokenized products gain price exposure but do not hold the actual underlying assets.
The announcement comes as the U.S. crypto industry enters a more permissive regulatory climate under President Donald Trump's administration. 
Recent regulatory developments include the SEC dropping enforcement cases against Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and other major crypto players, scaling back crypto enforcement units, and clarifying that meme coins are not securities. 
A new Crypto Task Force is also actively engaging with the industry through policy roundtables.
Durgee noted that the crypto space, once mired in restrictive oversight, is now benefiting from a more supportive environment. 
"We've moved from nothing but headwinds to having industrywide tailwinds," he said.
Republic will allow retail investors to purchase tokenized shares with investments ranging from $50 to $5,000, significantly lowering the usual barriers to entry. 
Private company shares are typically accessible to accredited investors with higher minimum investment thresholds.
The tokens will initially be priced based on secondary market valuations of SpaceX shares. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46116462/prediction-market-kalshi-raises-185m-surges-to-2b-valuation">Prediction Market Kalshi Raises $185M, Surges To $2B Valuation</a>
Why It Matters: The offering raises fresh regulatory questions, including how tokenized private equity aligns with disclosure rules, whether such structures could increase risks to retail investors, and how companies being represented will respond to this method of investment access.
Durgee said companies' approval isn't required for these offerings under the current securities framework, which was built on laws dating back to the 1930s. 
"People will really have to start questioning how they approach these innovations and how far they want to push the risk envelope," he added.
The push toward tokenization is gaining broader institutional interest. Proponents cite benefits like faster settlements, reduced transaction costs, increased transparency, and improved global accessibility for retail participants. 
Coinbase recently announced its intent to seek SEC approval to list tokenized public stocks, potentially expanding its offerings to compete directly with trading platforms like Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and eToro. 
Kraken has also signaled plans to offer 24/7 tokenized stock trading in international markets.
BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) CEO Larry Fink has called the tokenization of financial assets a critical step in transforming financial markets.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46114220/asias-microstrategy-metaplanet-acquires-additional-1234-bitcoin-as-etfs-extend-12-day-inflow-streak">&#8216;Asia&#8217;s MicroStrategy&#8217; Metaplanet Acquires Additional 1,234 Bitcoin As ETFs Extend 12-Day Inflow Streak</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

HOOD

Retail Investors Can Now Trade SpaceX Shares: Here's How

WIIM

NA stock has given up its prior loss. Nano Labs shares were trading lower after the company announced a $50 million offering of Class A ordinary stock and warrants.

Truist Securities analyst Michael Swartz maintains Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Buy and lowers the price target from $40 to $36.

Truist Securities Maintains Buy on Winnebago Industries, Lowers Price Target to $36

Viatris Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) and Opus Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">for presbyopia</a>.
Presbyopia is the gradual loss of near-focusing ability due to aging that typically becomes noticeable in the early to mid-40s. It is a nearly universal condition that, when uncorrected, contributes significantly to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46111517/viatris-announces-positive-top-line-results-from-second-pivotal-phase-3-vega-3-trial-of-mr-141-in-" rel="noreferrer noopener">vision-related disability</a>.
It affects nearly 128 million people in the United States, about 90% of adults over 45. By age 50, most Americans require some form of near-vision correction, such as reading glasses or multifocal lenses.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Viatris Chief R&amp;D Officer Philippe Martin said, &#8220;We are pleased with the positive results from the second pivotal Phase 3 trial, which reinforce our confidence in MR-141 and its benefit-risk profile as a potential, non-invasive option to support the millions of patients impacted by this condition.&#8221;
Significantly more patients treated in the MR-141 arm achieved the primary endpoint of Early Treatment Diabetic Retinopathy Study (ETDRS) (≥3-line) gain in binocular distance-corrected near visual acuity (DCNVA) and with less than five letters of loss in binocular best-corrected distance visual acuity (BCDVA) from baseline at 12 hours post-dose on Day 8, compared to placebo (p&lt;0.0001).
More patients treated in the MR-141 arm achieved ≥15-letters ETDRS (≥3-line) gain in DCNVA and with less than five letters of loss in BCDVA at 1-hour post-dose on Day 1 compared to those receiving placebo (p=0.0002).
Significant patient-reported functional benefits at Days 3, 8, and Week 6 were observed, with patients reporting satisfaction with near vision upon awakening (p&lt;0.0001) and satisfaction with their improvement in near vision (p&lt;0.0001).
Patient reported significant improvement in near vision in dim/low light at Days 3, 8 and Week 6 compared with placebo (p&lt;0.0001).
During the 6-week follow-up, no evidence of tachyphylaxis (an acute, sudden decrease in response to a drug) was observed.
MR-141 demonstrated a safety profile consistent with previous trials. No new safety signal was identified, and no treatment-related serious adverse events were reported in this study.
The most common (≥5%) treatment-emergent adverse events included conjunctival hyperemia, instillation site irritation, and dysgeusia, which were predominantly mild. A low rate of headache (2.6%) was reported over the study period.&nbsp;
Price Action: VTRS stock is up 1.97% at $9.065, and IRD stock is trading higher by 5.13% to $1.02 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46119135/tesla-set-for-rebound-thanks-to-robotaxis-and-strong-cash-flow-analyst" target="_blank" rel="noreferrer noopener">Tesla Set For Rebound Thanks To Robotaxis And Strong Cash Flow: Analyst</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

VTRS

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Truist Securities analyst Michael Ciarmoli initiates coverage on Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Hold rating and announces Price Target of $16.

Initiation

Truist Securities Initiates Coverage On Redwire with Hold Rating, Announces Price Target of $16

Company to Exit Molded Fiber Business; Additional Facility Changes Planned
MEMPHIS, Tenn., June 26, 2025 /PRNewswire/ -- International&nbsp;Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>, LSE: IPC))), a global leader in sustainable packaging, today announced a series of strategic changes to strengthen its North American operations and better serve customers.
As part of this initiative, the company will:
<ul>
<li>Exit the molded fiber business and convert the Reno, Nev. facility to support its packaging business</li>
<li>Close its packaging facility in Marion, Ohio</li>
<li>Close its recycling facility in Wichita, Kan.</li>
<li>Sell its containerboard mill in Xalapa, Mexico and its recycling plants in Xalapa and Apodaca, Mexico to Acabados de Papeles Santinados y Absorbentes (APSA).</li>
</ul>
In the U.S., these changes will impact approximately 110 hourly and 24 salaried employees. In Mexico, APSA intends to retain current onsite team members at each location. International Paper is committed to minimizing the impact through job placement in existing vacancies, retirements and other internal opportunities. Affected employees will also receive severance and outplacement support where possible.

International Paper To Exit Molded Fiber Business And Convert Reno, Nev. Facility To Support Its Packaging Business

<a href="https://www.bloomberg.com/news/articles/2025-06-26/bbva-favors-proceeding-with-sabadell-bid-if-investors-agree">https://www.bloomberg.com/news/articles/2025-06-26/bbva-favors-proceeding-with-sabadell-bid-if-investors-agree</a>

BBVA

'BBVA Favors Proceeding With Sabadell Bid If Investors Agree'- Bloomberg

Energy markets are in a bit of flux at the moment.
Last week, the idea of $120 oil and continued disruption from the Middle East conflict was at the top of expert minds.
This week, we seem to be back to everlasting peace, bliss, everlasting cooperation, rainbows, unicorns, and prosperity for all.
Oil prices have begun falling again, and the same experts who warned of spikes last week now expect to see crude back into the upper 50s.
Here is what I know about crude oil. The market has had a failed rally and is now back below the 50-week moving average by a smidge (highly technical term). Cash prices are opening right at the 200 days moving average.
For now Crude is still in a bearish mode in spite of last week's volatility related to the Iranian difficulties
Hedging volume by US producers soared last week as prices rose. Even as they locked in higher prices for future delivery, many producers were also buying out of the money call options just in case things got a little dodgier in Iran.
Producers were hedging and speculating a bit on a sustained conflict, but there is another group who looked at the price of the energy-related businesses they operate recently and decided that no matter what happened in the Middle East, the price of their stock was just too low.
The High-Yield Play: Mach Natural Resources (Ticker: MACH)
Sometimes the market serves up opportunities that seem almost too good to be true. Mach Natural Resources is one of those situations that demands a closer look, if only because of that eye-popping 15% plus distribution yield.
Mach operates in the Anadarko Basin, focusing on natural gas production across Western Oklahoma, Southern Kansas, and the Texas panhandle. This is not some wildcat exploration story. They are working proven reserves in established fields, which reduces the geological risk that plagues many energy ventures. The company went public in 2023, making it relatively new to the public markets but not new to the business of extracting hydrocarbons from the ground.
What immediately catches your attention is the ownership structure. William Wallace McMullen owns nearly 72% of the company, with Bayou City Energy Management controlling 66% overall. This level of insider ownership is unusual in public markets and suggests management has serious skin in the game. When McMullen dropped $4 million to buy another 280,400 shares this month, he was not making a token gesture.
The company has a variable dividend policy that over the last year has paid out over 18% in dividends. Yields that high usually signal either exceptional value or exceptional risk. In Mach&#8217;s case, analysts believe it is the former. Five analysts covering the stock have unanimous &#8220;Strong Buy&#8221; ratings with price targets averaging $24, suggesting 81% upside from current levels.
The company reported $0.61 in earnings per unit for the first quarter, slightly missing expectations but still generating substantial cash flow. Management projects $2.31 per unit in free cash flow for 2025, which provides reasonable coverage for the distribution at current commodity prices. The key phrase there is &#8220;current commodity prices.&#8221; Natural gas has been volatile, and Mach&#8217;s fortunes are tied directly to those price movements.
From a balance sheet perspective, Mach carries a debt-to-equity ratio of 0.64 with a current ratio of 1.24, indicating reasonable financial health. The return on equity of 24.33% reflects the leverage inherent in the business model, while the 14.53% return on invested capital suggests efficient managements.
The risk here is obvious: natural gas prices. If prices remain depressed, that distribution becomes unsustainable quickly. But with analysts projecting higher natural gas prices in 2025 and the company&#8217;s low-cost production profile, Mach appears positioned to benefit from any commodity recovery.
The Deep Value Turnaround: Amplify Energy (Ticker: AMPY)
While Mach offers high current income, Amplify Energy presents a classic deep value opportunity with the potential for substantial capital appreciation. The stock has been beaten down significantly, trading near its 52-week low of $2.58 after reaching $8.15 earlier in the cycle. Sometimes the market&#8217;s pessimism creates opportunity.
Amplify operates across multiple regions, giving it geographic diversification that many smaller energy companies lack. Their assets span Oklahoma, the Rockies, federal waters offshore Southern California, East Texas, North Louisiana, and the Eagle Ford. The California offshore operation, known as the Beta field, represents significant potential upside but requires oil prices above $60 per barrel to justify development.
The first quarter results told an interesting story. While revenue of $72 million slightly missed expectations, earnings per share of $3.80 crushed analyst estimates of $0.21. This dramatic outperformance suggests the company&#8217;s operational improvements are gaining traction. Management has focused on cost reduction and cash flow improvement, with debt reduction being a primary goal.
What really gets my attention is the insider activity. In the past 30days, insiders have purchased 391,176 shares worth $1.31 million. Last week director Christopher Hamm bought 77,176 shares at $3.67, while COO Daniel Furbee added 10,000 shares at $2.97 at the end of May. When management is backing up their optimism with personal capital, it is worth paying attention.
The analyst community sees substantial upside. With price targets ranging from $8.50 to $11.00 and an average of $9.67, the Street is pricing in 150% upside potential. Seven analysts have issued buy ratings with zero holds or sells in the current month. This level of optimism from professionals who have studied the company&#8217;s assets suggests the current price reflects excessive pessimism.
The Steady Eddie: ConocoPhillips (Ticker: COP)
If Mach and Amplify represent the more speculative end of energy investing, ConocoPhillips stands as the sector&#8217;s steady performer. With a $121 billion market cap, this is one of the world&#8217;s largest independent exploration and production companies, offering global diversification and operational scale that smaller companies cannot match.
ConocoPhillips operates across six segments spanning Alaska to Asia Pacific, but their crown jewel remains the Lower 48 operations. They produce 833 thousand barrels of oil equivalent per day from the Permian Basin alone, making them a major player in America&#8217;s most important shale field. Add in 296 thousand barrels daily from the Eagle Ford and 151 thousand from the Bakken, and you are looking at a company with tier-one assets in tier-one basins.
The first quarter showed the company&#8217;s resilience. Despite a 6% decline in realized prices to $53.34 per barrel, production increased 487 thousand barrels daily year-over-year to 2.389 million barrels equivalent. This volume growth helped deliver $2.8 billion in earnings, up from $2.6 billion in the prior year. Management&#8217;s ability to grow production while reducing both capital expenditure guidance to $12.3-12.6 billion and operating cost guidance to $10.7-10.9 billion demonstrates operational excellence.
What sets ConocoPhillips apart is their shareholder-friendly capital allocation. The quarterly dividend of $0.78 per share yields 3.58% annually, with a sustainable payout ratio of 38.98%. Management raised the dividend 34% in the third quarter of 2024, signaling confidence in cash flow sustainability. Beyond dividends, the company returned $9.1 billion to shareholders in 2024, including $5.5 billion in share buybacks.
The share repurchase program deserves particular attention. Management increased their authorization by $20 billion and plans to return $10 billion to shareholders in 2025. At current prices, this represents meaningful ownership accretion for remaining shareholders. When combined with the dividend, total shareholder yield approaches impressive levels.
Recent insider activity reinforces management confidence. Executive Vice President Kirk Johnson purchased 5,300 shares at $94.24 last week, investing nearly $500,000 of personal capital.
Institutional ownership exceeds 75%, with JPMorgan Chase holding 47.2 million shares and Price T. Rowe Associates owning 40.3 million shares. Berkshire Hathaway&#8217;s continued position adds Warren Buffett&#8217;s implicit endorsement to the investment thesis.
Eighteen Wall Street analysts cover the stock with a strong buy consensus, setting price targets averaging $113.50 with a range from $95 to $130. This suggests 20-21% upside potential, which when combined with the 3.58% dividend yield, offers attractive total return prospects.
Insiders have been slowly accumulating energy stocks for several months now.
This is not about end demand and pricing for crude oil and natural gas over the next few months.
It is about the growing demand we will ss over rh next several decades.

Opinion

AMPY

Alpha Buying: Volatility Be Damned—These Energy Stocks Have a Plan

<h3>Gainers</h3>
<ul>
<li>Live Ventures (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVE#NASDAQ">LIVE</a>) stock moved upwards by 83.6% to $15.51 during Thursday's regular session. The company's market cap stands at $25.9 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares rose 37.95% to $1.02. The market value of their outstanding shares is at $52.9 million. </li>
<li>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock rose 25.94% to $7.14. The company's market cap stands at $3.1 billion. </li>
<li>Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) shares moved upwards by 19.15% to $2.42. The market value of their outstanding shares is at $46.6 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares rose 18.92% to $7.73. The market value of their outstanding shares is at $3.5 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares moved upwards by 14.24% to $1.85. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares decreased by 21.5% to $0.21 during Thursday's regular session. The company's market cap stands at $30.3 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares fell 20.56% to $0.71. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 8.8% to $0.31. The company's market cap stands at $1.9 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares decreased by 8.47% to $7.95. The company's market cap stands at $154.7 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock decreased by 8.36% to $8.56. The market value of their outstanding shares is at $477.3 million. </li>
<li>Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWWP#NASDAQ">POWWP</a>) shares decreased by 8.23% to $21.1. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EZGO

JFBR

LIVE

MULN

POWWP

SYPR

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

Press Releases

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Earnings

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Clear Street Launches Healthcare & Biotechnology Equity Research

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

JANX

MLTX

NUVB

PTGX

YMAB

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Aligos Therapeutics

Annovis Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Avalo Therapeutics

Celularity

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OS Therapies

PepGen

Pluri

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

RenovoRx

Senti Biosciences

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Chardan Capital

HC Wainwright & Co.

Piper Sandler

Canaccord Genuity

JP Morgan

센추리 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) 주가는 수요일(27일)에 20.74% 상승한 주당 1.63달러로 마감하면서, 10월 1일 이후 거의 한 달 만에 가장 높은 가격 변동폭을 기록했다. 또한 주가는 2023년 12월 6일 이후 11개월여 만에 하루 만에 가장 큰 폭으로 상승한 것이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-668715" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1024x251.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1024x251.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-300x74.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-768x188.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart-1536x376.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28011655/century-chart.png 1738w" alt="" width="1024" height="251" /></figure>
무슨 일 있었나: 수요일 미 증권거래위원회(SEC) 공시에 따르면 캐스딘 캐피털은 바이오 기업 센추리 테라퓨틱스의 주식 1,380,000주를 추가로 인수하여 지분을 43% 가까이 늘렸다.
이러한 거래가 완료된 후 캐스딘 캐피털은 총 4,592,316주, 즉 5.4%의 센추리 테라퓨틱스 주식을 보유하게 되었다. 서류에 따르면 센추리 주식은 주당 1.35달러에 매입되었고, 거래 후 센추리 테라퓨틱스는 캐스딘 포트폴리오의 0.12%를 차지하게 되었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%94%ED%98%B8%ED%99%94%ED%8F%90-%EC%95%A0%EB%84%90%EB%A6%AC%EC%8A%A4%ED%8A%B8-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EC%8A%A4%ED%8A%B8%EB%9E%98%ED%8B%B0%EC%A7%80%EC%9D%98-%EC%A0%84%ED%99%98/" target="_blank" rel="noopener">암호화폐 애널리스트, 마이크로스트레티지의 전환사채로 인한 청산 위험 경고</a>
왜 중요한가: 센추리 주가는 캐스딘의 추가 인수 이후 36% 급등했던 2023년 12월 6일 이후 일일 최대 상승을 기록하면서 21% 가까이 급등했다.
뉴욕에 본사를 둔 투자 회사 캐스딘 캐피털은 바이오 분야 투자를 전문으로 하는 회사다. 15억 달러 규모의 주식 포트폴리오를 보유하고 있으며, 주요 보유 종목으로는 바이오라이프 솔루션스(BLFS)와 사렙타 테라퓨틱스(SRPT)가 있다.
이미지 출처: Unsplash 
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Century Therapeutics

뉴스

에 대한 최신 뉴스 Century Therapeutics (NASDAQ:IPSC) 주식

목요일, 11월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌